清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction

射血分数 利钠肽 心力衰竭 心脏病学 临床终点 内科学 安慰剂 医学 子群分析 置信区间 随机对照试验 替代医学 病理
作者
Robert J. Mentz,Amanda Stebbins,Javed Butler,Chern‐En Chiang,Justin A. Ezekowitz,Adrian F. Hernandez,Robert Hilkert,Carolyn S.P. Lam,Kenneth McDonald,Christopher M. O’Connor,Burkert Pieske,Piotr Ponikowski,Lothar Roessig,Nancy K. Sweitzer,Adriaan A. Voors,Kevin J. Anstrom,Paul W. Armstrong
出处
期刊:Jacc-Heart Failure [Elsevier BV]
卷期号:12 (5): 839-846 被引量:4
标识
DOI:10.1016/j.jchf.2023.12.005
摘要

In VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction), vericiguat compared with placebo reduced cardiovascular death or heart failure (HF) hospitalization in patients with HF with reduced ejection fraction. This study explored the association between vericiguat and recurrent hospitalizations and subsequent mortality after HF hospitalization. The treatment effect of vericiguat on the burden of HF hospitalizations was evaluated by assessing total HF hospitalization and cardiovascular death in the overall trial and based on baseline N-terminal pro–B-type natriuretic peptide levels with and without adjustment for VICTORIA model covariates (ie, baseline variables associated with the primary endpoint) assessed via the Andersen-Gill method. Associations between vericiguat and recurrent hospitalization and mortality adjusted for VICTORIA model covariates are reported. There were 1,222 total HF hospitalizations and cardiovascular deaths among 2,526 patients in the vericiguat group and 1,336 total events among 2,524 patients in the placebo group (unadjusted HR: 0.89 [95% CI: 0.81-0.97] and adjusted HR: 0.92 [95% CI: 0.84-1.01]). In the subgroup with N-terminal pro–B-type natriuretic peptide levels ≤2,816 pg/mL (ie, Q1 and Q2; median or below), there was a suggestion of a benefit with vericiguat (adjusted HRs of 0.80 [95% CI: 0.64-1.01] and 0.77 [95% CI: 0.62-0.94], respectively) compared with those above this value (adjusted HRs of 1.12 [95% CI: 0.93-1.34] and 0.87 [95% CI: 0.74-1.04] for Q3 and Q4). There was no significant difference in treatment effect between patients with vs without an HF hospitalization. After HF hospitalization, the all-cause mortality rate (events per 100 patient-years) was 48.6 for vericiguat and 44.1 for placebo. Additional investigation of the association between vericiguat and cardiovascular death and total HF hospitalizations by recurrent event analysis did not show a statistically significant reduction in events. Mortality was high after HF hospitalization, emphasizing the need for further therapies to reduce morbidity and mortality. (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction [VICTORIA]; NCT02861534)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
alex_zhao完成签到,获得积分10
1秒前
量子星尘发布了新的文献求助10
9秒前
文献完成签到 ,获得积分10
47秒前
能干觅夏完成签到 ,获得积分10
52秒前
1分钟前
glanceofwind完成签到 ,获得积分10
1分钟前
beplayer1完成签到,获得积分10
1分钟前
1分钟前
量子星尘发布了新的文献求助10
2分钟前
kean1943完成签到,获得积分10
2分钟前
muriel完成签到,获得积分10
2分钟前
2分钟前
爱思考的小笨笨完成签到,获得积分10
3分钟前
3分钟前
3分钟前
nojego完成签到,获得积分10
3分钟前
量子星尘发布了新的文献求助10
3分钟前
3分钟前
MYZ完成签到,获得积分10
4分钟前
Spring完成签到,获得积分10
4分钟前
4分钟前
科研通AI2S应助科研通管家采纳,获得10
4分钟前
科研通AI2S应助科研通管家采纳,获得10
4分钟前
量子星尘发布了新的文献求助10
4分钟前
紫熊发布了新的文献求助10
4分钟前
4分钟前
小瓶盖完成签到 ,获得积分10
5分钟前
负责以山完成签到 ,获得积分10
5分钟前
5分钟前
5分钟前
量子星尘发布了新的文献求助10
5分钟前
6分钟前
紫熊发布了新的文献求助10
6分钟前
naczx完成签到,获得积分0
6分钟前
6分钟前
冷傲半邪完成签到,获得积分10
6分钟前
量子星尘发布了新的文献求助10
7分钟前
7分钟前
7分钟前
7分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976683
求助须知:如何正确求助?哪些是违规求助? 3520770
关于积分的说明 11204819
捐赠科研通 3257565
什么是DOI,文献DOI怎么找? 1798733
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806629